🚀 VC round data is live in beta, check it out!
Aligos Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Aligos Therapeutics and similar public comparables like Cessatech, Scilex Holding, Xilio Therapeutics, Cynata Therapeutics and more.
Aligos Therapeutics Overview
About Aligos Therapeutics
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.
Founded
2018
HQ
Employees
70
Website
Sectors
Financials (LTM)
Market Cap
$49M
Aligos Therapeutics Financials
Aligos Therapeutics reported last 12-month revenue of $2M and negative EBITDA of ($92M).
In the same LTM period, Aligos Therapeutics generated $2M in gross profit, ($92M) in EBITDA losses, and had net loss of ($45M).
Revenue (LTM)
Aligos Therapeutics P&L
In the most recent fiscal year, Aligos Therapeutics reported revenue of $2M and EBITDA of ($85M).
Aligos Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $2M | XXX | $2M | XXX | XXX | XXX |
| Gross Profit | $2M | XXX | — | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | — | XXX | XXX | XXX |
| EBITDA | ($92M) | XXX | ($85M) | XXX | XXX | XXX |
| EBITDA Margin | (4653%) | XXX | (3897%) | XXX | XXX | XXX |
| EBIT Margin | (4647%) | XXX | (4025%) | XXX | XXX | XXX |
| Net Profit | ($45M) | XXX | ($24M) | XXX | XXX | XXX |
| Net Margin | (2258%) | XXX | (1107%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Aligos Therapeutics Stock Performance
Aligos Therapeutics has current market cap of $49M.
Market Cap Evolution
Aligos Therapeutics' stock price is $7.94.
| Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|
| $49M | -0.6% | XXX | XXX | XXX | $-3.91 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAligos Therapeutics Valuation Multiples
Aligos Therapeutics trades at (11.9x) EV/Revenue multiple, and 0.3x EV/EBITDA.
EV / Revenue (LTM)
Aligos Therapeutics Financial Valuation Multiples
As of April 11, 2026, Aligos Therapeutics has market cap of $49M.
Equity research analysts estimate Aligos Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Aligos Therapeutics has a P/E ratio of (1.1x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $49M | XXX | $49M | XXX | XXX | XXX |
| EV (current) | ($23M) | XXX | ($23M) | XXX | XXX | XXX |
| EV/Revenue | (11.9x) | XXX | (10.7x) | XXX | XXX | XXX |
| EV/EBITDA | 0.3x | XXX | 0.3x | XXX | XXX | XXX |
| EV/EBIT | 0.3x | XXX | 0.3x | XXX | XXX | XXX |
| EV/Gross Profit | (11.9x) | XXX | — | XXX | XXX | XXX |
| P/E | (1.1x) | XXX | (2.0x) | XXX | XXX | XXX |
| EV/FCF | 0.3x | XXX | 0.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Aligos Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Aligos Therapeutics Margins & Growth Rates
Aligos Therapeutics' revenue in the last 12 month declined by (23%).
Aligos Therapeutics' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $1.3M for the same period.
Aligos Therapeutics' rule of 40 is (7429%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Aligos Therapeutics' rule of X is (7481%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Aligos Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | (23%) | XXX | (35%) | XXX | XXX | XXX |
| EBITDA Margin | (4653%) | XXX | (3897%) | XXX | XXX | XXX |
| EBITDA Growth | 15% | XXX | 23% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | (7429%) | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | (7481%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $1.3M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 1071% | XXX | 948% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 3627% | XXX | 3178% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 4125% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Aligos Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Cessatech | XXX | XXX | XXX | XXX | XXX | XXX |
| Scilex Holding | XXX | XXX | XXX | XXX | XXX | XXX |
| Xilio Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Cynata Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Vicapsys | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Aligos Therapeutics M&A Activity
Aligos Therapeutics acquired XXX companies to date.
Last acquisition by Aligos Therapeutics was on XXXXXXXX, XXXXX. Aligos Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Aligos Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialAligos Therapeutics Investment Activity
Aligos Therapeutics invested in XXX companies to date.
Aligos Therapeutics made its latest investment on XXXXXXXX, XXXXX. Aligos Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Aligos Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Aligos Therapeutics
| When was Aligos Therapeutics founded? | Aligos Therapeutics was founded in 2018. |
| Where is Aligos Therapeutics headquartered? | Aligos Therapeutics is headquartered in United States. |
| How many employees does Aligos Therapeutics have? | As of today, Aligos Therapeutics has over 70 employees. |
| Who is the CEO of Aligos Therapeutics? | Aligos Therapeutics' CEO is Lawrence M. Blatt. |
| Is Aligos Therapeutics publicly listed? | Yes, Aligos Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Aligos Therapeutics? | Aligos Therapeutics trades under ALGS ticker. |
| When did Aligos Therapeutics go public? | Aligos Therapeutics went public in 2020. |
| Who are competitors of Aligos Therapeutics? | Aligos Therapeutics main competitors are Cessatech, Scilex Holding, Xilio Therapeutics, Cynata Therapeutics. |
| What is the current market cap of Aligos Therapeutics? | Aligos Therapeutics' current market cap is $49M. |
| What is the current revenue of Aligos Therapeutics? | Aligos Therapeutics' last 12 months revenue is $2M. |
| What is the current revenue growth of Aligos Therapeutics? | Aligos Therapeutics revenue growth (NTM/LTM) is (23%). |
| What is the current EV/Revenue multiple of Aligos Therapeutics? | Current revenue multiple of Aligos Therapeutics is (11.9x). |
| Is Aligos Therapeutics profitable? | No, Aligos Therapeutics is not profitable. |
| What is the current EBITDA of Aligos Therapeutics? | Aligos Therapeutics has negative EBITDA and is not profitable. |
| What is Aligos Therapeutics' EBITDA margin? | Aligos Therapeutics' last 12 months EBITDA margin is (4653%). |
| What is the current EV/EBITDA multiple of Aligos Therapeutics? | Current EBITDA multiple of Aligos Therapeutics is 0.3x. |
| What is the current FCF of Aligos Therapeutics? | Aligos Therapeutics' last 12 months FCF is ($87M). |
| What is Aligos Therapeutics' FCF margin? | Aligos Therapeutics' last 12 months FCF margin is (4394%). |
| What is the current EV/FCF multiple of Aligos Therapeutics? | Current FCF multiple of Aligos Therapeutics is 0.3x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.